NCT06906900View on ClinicalTrials.gov

A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

February 17, 2027

Study Completion Date

February 17, 2029

Conditions
Spinal Metastasis
Interventions
DEVICE

TTF-200M and TTF-200A systems

Participants will receive one cycle and treatment will continue as long as the doctor thinks it is in the participant's best interest.

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER